Accumulation of the endogenous NO synthase (NOS) inhibitors asymmetric dimethyl arginine (ADMA) and Ng-monomethyl-L-arginine (L-NMMA) is a major risk factor for cardiovascular diseases including hypertension, coronary artery disease, stroke, diabetes and atherosclerosis. These endogenous NOS inhibitors compete with L-arginine to inhibit NO production by NOS. ADMA and L-NMMA are eliminated principally by dimethylarginine dimethylaminohydrolase (DDAH) with a small contribution from renal excretion. It is reported that ADMA and L-NMMA are degraded by both DDAH1 and DDAH2, but the relative contributions of DDAH1 and DDAH2 have been controversial. Furthermore, whether DDAH1 can exert effects on vascular function beyond regulation of NO production is unknown. Using novel tissue specific DDAH1 deficient mice and global DDAH1 gene deficient mice generated in our laboratory, our preliminary data demonstrate that DDAH1 plays an essential role in degrading the endogenous NOS inhibitors, and that DDAH1 distributed in endothelial cells plays an important role in regulating vascular endothelial NO production and endothelial cell growth and injury repair. Most interestingly, our preliminary data further demonstrated that DDAH1 also regulates endothelial cell function through a novel molecular pathway independent of degradation the of endogenous NOS inhibitors. Based on these new findings, we propose to test two hypotheses. First, we hypothesize that DDAH1 is the principal enzyme responsible for degrading ADMA and L-NMMA. Second, we hypothesize that DDAH1 exerts additional actions beyond its role in degrading ADMA and L-NMMA that regulate vascular endothelial cell growth and injury repair. To test these hypotheses, we have generated a novel tissue specific endothelial-DDAH1 KO (endo-DDAH1 KO) mouse strain and a global DDAH1 KO mouse strain. The proposed studies will utilize in vitro and in vivo approaches to provide new insight into the function of the endogenous NOS inhibitors, as well as novel molecular mechanisms by which DDAH1 acts to maintain vascular endothelial cell growth and injury repair.

Public Health Relevance

Accumulation of the endogenous nitric oxide synthase (NOS) inhibitors asymmetric dimethyl arginine (ADMA) and Ng-monomethyl-L-arginine (L-NMMA) is a major risk factor for cardiovascular diseases including hypertension, coronary artery disease, stroke, diabetes and atherosclerosis. DDAH1 degrades ADMA and L-NMMA to increase nitric oxide production. The proposed studies will integrate in vitro and in vivo approaches to provide new insight into the function of the endogenous NOS inhibitors, as well as novel molecular mechanisms by which DDAH1 acts to maintain vascular endothelial cell growth and injury repair.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HL098669-01A1
Application #
7989487
Study Section
Special Emphasis Panel (ZRG1-VH-F (90))
Program Officer
Gao, Yunling
Project Start
2010-08-01
Project End
2012-06-30
Budget Start
2010-08-01
Budget End
2011-06-30
Support Year
1
Fiscal Year
2010
Total Cost
$264,250
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Liu, Xiaohong; Xu, Xin; Shang, Ruru et al. (2018) Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease. Nitric Oxide 78:113-120
Wang, Huan; Hou, Lei; Kwak, Dongmin et al. (2016) Increasing Regulatory T Cells With Interleukin-2 and Interleukin-2 Antibody Complexes Attenuates Lung Inflammation and Heart Failure Progression. Hypertension 68:114-22
Wang, Huan; Kwak, Dongmin; Fassett, John et al. (2016) CD28/B7 Deficiency Attenuates Systolic Overload-Induced Congestive Heart Failure, Myocardial and Pulmonary Inflammation, and Activated T Cell Accumulation in the Heart and Lungs. Hypertension 68:688-96
Liu, Xiaoyu; Hou, Lei; Xu, Dachun et al. (2016) Effect of asymmetric dimethylarginine (ADMA) on heart failure development. Nitric Oxide 54:73-81
Lu, Zhongbing; Xu, Xin; Fassett, John et al. (2014) Loss of the eukaryotic initiation factor 2? kinase general control nonderepressible 2 protects mice from pressure overload-induced congestive heart failure without affecting ventricular hypertrophy. Hypertension 63:128-35
Wang, Huan; Xu, Xin; Fassett, John et al. (2014) Double-stranded RNA-dependent protein kinase deficiency protects the heart from systolic overload-induced congestive heart failure. Circulation 129:1397-406
Chen, Yingjie; Zhang, Ping; Li, Jingxin et al. (2014) Inducible nitric oxide synthase inhibits oxygen consumption in collateral-dependent myocardium. Am J Physiol Heart Circ Physiol 306:H356-62
Xu, Xin; Lu, Zhongbing; Fassett, John et al. (2014) Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase ?2. Hypertension 63:723-8
Bache, Robert J; Chen, Yingjie (2014) NOX2-induced myocardial fibrosis and diastolic dysfunction: role of the endothelium. J Am Coll Cardiol 63:2742-4
Liu, Xiaoyu; Kwak, Dongmin; Lu, Zhongbing et al. (2014) Endoplasmic reticulum stress sensor protein kinase R-like endoplasmic reticulum kinase (PERK) protects against pressure overload-induced heart failure and lung remodeling. Hypertension 64:738-44

Showing the most recent 10 out of 25 publications